RNAC Stock Forecast & Price Target

Cartesian Therapeutics Inc is currently demonstrating promising advancements in its clinical-stage biopharmaceutical development, particularly with its Descartes-08 therapy, which has shown sustained clinically meaningful improvements and a favorable safety profile compared to traditional treatments. The recent Phase 2b data highlighted significant average reductions in the MG-ADL at 12-month dosing intervals, indicating the potential for better treatment outcomes in biologic-naive patients and an expanded patient population. Additionally, the therapeutic mechanism supported by significant biomarker reductions further validates the efficacy of Descartes-08, positioning the company favorably within the competitive landscape of autoimmune disease treatments.

Cartesian Therapeutics Inc is experiencing a decline in cash reserves, falling from $162.1 million in Q2 2025 to $145.1 million in Q3 2025, raising concerns about the sustainability of its operations despite management's assurances that current funds will last into mid-2027. The market is assigning minimal value to Cartesian’s lead candidate, Descartes-08, in treating myasthenia gravis, even with a well-supported Phase 3 program that has received regulatory backing, reflecting investor skepticism. Additionally, the company faces challenges in demonstrating the efficacy of treatments amid rising patient burden due to the need for multiple cycles of therapy and high costs, further contributing to a negative outlook.